and anti-IgE. Combinations of rhinitis, asthma, and IgE captured information on disease pathophysiology. Results: Omalizumab is a monoclonal antibody targeting the high-affinity receptor binding ...

and one anti-CD38 monoclonal antibody. NICE recommended Elrexfio and Tecvayli with what it calls 'optimised' guidance, which means that they can be used with modifications to the MHRA-approved ...

Biogen has revealed encouraging phase 2 results with its anti-CD38 antibody felzartamab in rare kidney disease IgA nephropathy (IgAN), which it hopes could join a series of first-in-class ...

No writing assistance was utilized in the production of this manuscript. Monoclonal antibodies are novel therapeutic agents used with great success in the treatment of rheumatoid arthritis (RA).

CD38 monoclonal antibodies, bispecific antibodies, and CAR T-cell therapies are pivotal in multiple myeloma management, offering deep responses and manageable toxicities. Comprehensive molecular ...

of intravenous HexaBody-CD38 versus subcutaneous daratumumab in patients with anti-CD38 antibody- naïve relapsed or refractory multiple myeloma. Preliminary data submitted by Genmab to J&J ...

I-Mab anticipates its first product launch in 2021–2022, for the anti-CD38 monoclonal antibody TJ202, which is currently in a phase 3 trial and a registrational trial in parallel in Greater ...

“This is a natural place for a platform proof-of-concept, because monoclonal antibodies against CD38 have been approved for the indication, and anti-CD3 antibodies have been shown to redirect ...

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.